Arvin K. George, MD, and Srinivas Vourganti, MD presented “Panel Discussion: PROSTATE SAMPLING AND SPACING” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
How to cite: George, Arvin K; Vourganti, Srinivas. “Panel Discussion: PROSTATE SAMPLING AND SPACING.” November, 2023. Accessed Nov 2024. https://grandroundsinurology.com/panel-discussion-prostate-sampling-and-spacing/
Panel Discussion: PROSTATE SAMPLING AND SPACING – Summary
Arvin K. George, MD, and Srinivas Vourganti, MD
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Arvin George, MD, serves as Director of Prostate Cancer Programs and Associate Professor (PAR) of Urology at Johns Hopkins School of Medicine in Baltimore, Maryland. He is a urologic surgeon who specializes in the diagnosis and management of genitourinary cancers. After obtaining his medical degree from the Royal College of Surgeons in Ireland, he completed his urology residency at the Smith Institute for Urology at the Hofstra North Shore-LIJ School of Medicine. He remained there to complete his endourology fellowship in New York, gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. George’s research interests include minimally-invasive and image-guided treatments, functional prostate imaging, and focal therapy for prostate cancer. His research aims to identify appropriate use for imaging in diagnosis, risk stratification, and management of prostate cancer, including active surveillance and selection/treatment of patients with novel focal therapy modalities.
